Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.

Walle LV, Stowe IB, Šácha P, Lee BL, Demon D, Fossoul A, Van Hauwermeiren F, Saavedra PHV, Šimon P, Šubr V, Kostka L, Stivala CE, Pham VC, Staben ST, Yamazoe S, Konvalinka J, Kayagaki N, Lamkanfi M.

PLoS Biol. 2019 Oct 16;17(10):e3000529. doi: 10.1371/journal.pbio.3000529. eCollection 2019 Oct.

2.

Augmentation of EPR Effect and Efficacy of Anticancer Nanomedicine by Carbon Monoxide Generating Agents.

Fang J, Islam R, Islam W, Yin H, Subr V, Etrych T, Ulbrich K, Maeda H.

Pharmaceutics. 2019 Jul 16;11(7). pii: E343. doi: 10.3390/pharmaceutics11070343.

3.

Singlet oxygen phosphorescence detection in vivo identifies PDT-induced anoxia in solid tumors.

Hackbarth S, Islam W, Fang J, Šubr V, Röder B, Etrych T, Maeda H.

Photochem Photobiol Sci. 2019 Jun 12;18(6):1304-1314. doi: 10.1039/c8pp00570b.

PMID:
30994640
4.

Identification of Protein Targets of Bioactive Small Molecules Using Randomly Photomodified Probes.

Šimon P, Knedlík T, Blažková K, Dvořáková P, Březinová A, Kostka L, Šubr V, Konvalinka J, Šácha P.

ACS Chem Biol. 2018 Dec 21;13(12):3333-3342. doi: 10.1021/acschembio.8b00791. Epub 2018 Dec 7.

PMID:
30489064
5.

Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.

Islam W, Fang J, Imamura T, Etrych T, Subr V, Ulbrich K, Maeda H.

Mol Cancer Ther. 2018 Dec;17(12):2643-2653. doi: 10.1158/1535-7163.MCT-18-0696. Epub 2018 Sep 19.

PMID:
30232144
6.

N-(2-Hydroxypropyl)methacrylamide-Based Linear, Diblock, and Starlike Polymer Drug Carriers: Advanced Process for Their Simple Production.

Koziolová E, Kostka L, Kotrchová L, Šubr V, Konefal R, Nottelet B, Etrych T.

Biomacromolecules. 2018 Oct 8;19(10):4003-4013. doi: 10.1021/acs.biomac.8b00973. Epub 2018 Sep 19.

PMID:
30180562
7.

N-(2-hydroxypropyl)methacrylamide polymer conjugated pyropheophorbide-a, a promising tumor-targeted theranostic probe for photodynamic therapy and imaging.

Fang J, Šubr V, Islam W, Hackbarth S, Islam R, Etrych T, Ulbrich K, Maeda H.

Eur J Pharm Biopharm. 2018 Sep;130:165-176. doi: 10.1016/j.ejpb.2018.06.005. Epub 2018 Jun 8.

PMID:
29885851
8.

Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles.

Neburkova J, Sedlak F, Zackova Suchanova J, Kostka L, Sacha P, Subr V, Etrych T, Simon P, Barinkova J, Krystufek R, Spanielova H, Forstova J, Konvalinka J, Cigler P.

Mol Pharm. 2018 Aug 6;15(8):2932-2945. doi: 10.1021/acs.molpharmaceut.7b00889. Epub 2018 Feb 13.

PMID:
29389139
9.

Inhibitor-Decorated Polymer Conjugates Targeting Fibroblast Activation Protein.

Dvořáková P, Bušek P, Knedlík T, Schimer J, Etrych T, Kostka L, Stollinová Šromová L, Šubr V, Šácha P, Šedo A, Konvalinka J.

J Med Chem. 2017 Oct 26;60(20):8385-8393. doi: 10.1021/acs.jmedchem.7b00767. Epub 2017 Oct 16.

PMID:
28953383
10.

Photodynamic therapy and imaging based on tumor-targeted nanoprobe, polymer-conjugated zinc protoporphyrin.

Fang J, Liao L, Yin H, Nakamura H, Subr V, Ulbrich K, Maeda H.

Future Sci OA. 2015 Nov 1;1(3):FSO4. doi: 10.4155/fso.15.2. eCollection 2015 Nov.

11.

Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate.

Sivak L, Subr V, Tomala J, Rihova B, Strohalm J, Etrych T, Kovar M.

Biomaterials. 2017 Jan;115:65-80. doi: 10.1016/j.biomaterials.2016.11.013. Epub 2016 Nov 12.

PMID:
27886555
12.

Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors.

Koziolová E, Janoušková O, Cuchalová L, Hvězdová Z, Hraběta J, Eckschlager T, Sivák L, Ulbrich K, Etrych T, Šubr V.

J Control Release. 2016 Jul 10;233:136-46. doi: 10.1016/j.jconrel.2016.05.036. Epub 2016 May 14.

PMID:
27189135
13.

Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies.

Ulbrich K, Holá K, Šubr V, Bakandritsos A, Tuček J, Zbořil R.

Chem Rev. 2016 May 11;116(9):5338-431. doi: 10.1021/acs.chemrev.5b00589. Epub 2016 Apr 25. Review.

PMID:
27109701
14.

Polymer inhibitors of ABC transporter overcoming multidrug resistance: Synthesis, characterization and in vitro evaluation.

Šubr V, Koziolová E, Sivák L, Říhová B, Kovář M, Ulbrich K.

J Control Release. 2015 Sep 10;213:e107-8. doi: 10.1016/j.jconrel.2015.05.180. Epub 2015 Aug 19. No abstract available.

PMID:
27005035
15.

iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties.

Šácha P, Knedlík T, Schimer J, Tykvart J, Parolek J, Navrátil V, Dvořáková P, Sedlák F, Ulbrich K, Strohalm J, Majer P, Šubr V, Konvalinka J.

Angew Chem Int Ed Engl. 2016 Feb 12;55(7):2356-60. doi: 10.1002/anie.201508642. Epub 2016 Jan 8.

16.

Novel IL-2-Poly(HPMA)Nanoconjugate Based Immunotherapy.

Votavova P, Tomala J, Subr V, Strohalm J, Ulbrich K, Rihova B, Kovar M.

J Biomed Nanotechnol. 2015 Sep;11(9):1662-73.

PMID:
26485935
17.

Nanotherapeutics shielded with a pH responsive polymeric layer.

Kostka L, Šubr V, Laga R, Chytil P, Ulbrich K, Seymour LW, Etrych T.

Physiol Res. 2015;64 Suppl 1:S29-40.

18.

Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro.

Subr V, Sivák L, Koziolová E, Braunová A, Pechar M, Strohalm J, Kabešová M, Ríhová B, Ulbrich K, Kovář M.

Biomacromolecules. 2014 Aug 11;15(8):3030-43. doi: 10.1021/bm500649q. Epub 2014 Jul 10.

PMID:
24978588
19.

Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.

Etrych T, Subr V, Laga R, Ríhová B, Ulbrich K.

Eur J Pharm Sci. 2014 Jul 16;58:1-12. doi: 10.1016/j.ejps.2014.02.016. Epub 2014 Mar 13.

PMID:
24632485
20.

Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo.

Prill JM, Subr V, Pasquarelli N, Engler T, Hoffmeister A, Kochanek S, Ulbrich K, Kreppel F.

PLoS One. 2014 Jan 27;9(1):e82716. doi: 10.1371/journal.pone.0082716. eCollection 2014.

21.

In Vivo Nanotoxicity Testing using the Zebrafish Embryo Assay.

Rizzo LY, Golombek SK, Mertens ME, Pan Y, Laaf D, Broda J, Jayapaul J, Möckel D, Subr V, Hennink WE, Storm G, Simon U, Jahnen-Dechent W, Kiessling F, Lammers T.

J Mater Chem B. 2013 Jun 10;1. doi: 10.1039/C3TB20528B.

22.

Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound.

Carlisle R, Choi J, Bazan-Peregrino M, Laga R, Subr V, Kostka L, Ulbrich K, Coussios CC, Seymour LW.

J Natl Cancer Inst. 2013 Nov 20;105(22):1701-10. doi: 10.1093/jnci/djt305. Epub 2013 Oct 29.

23.

Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo.

Nakamura H, Liao L, Hitaka Y, Tsukigawa K, Subr V, Fang J, Ulbrich K, Maeda H.

J Control Release. 2013 Feb 10;165(3):191-8. doi: 10.1016/j.jconrel.2012.11.017. Epub 2012 Dec 3.

PMID:
23220104
24.

HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.

Etrych T, Subr V, Strohalm J, Sírová M, Ríhová B, Ulbrich K.

J Control Release. 2012 Dec 28;164(3):346-54. doi: 10.1016/j.jconrel.2012.06.029. Epub 2012 Jun 30.

PMID:
22759979
25.

Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer.

Green NK, Hale A, Cawood R, Illingworth S, Herbert C, Hermiston T, Subr V, Ulbrich K, van Rooijen N, Seymour LW, Fisher KD.

Nanomedicine (Lond). 2012 Nov;7(11):1683-95. doi: 10.2217/nnm.12.50. Epub 2012 Jun 18.

PMID:
22709345
26.

Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway.

Seki T, Carroll F, Illingworth S, Green N, Cawood R, Bachtarzi H, Subr V, Fisher KD, Seymour LW.

J Control Release. 2011 Dec 20;156(3):381-9. doi: 10.1016/j.jconrel.2011.08.022. Epub 2011 Aug 22.

PMID:
21884739
27.

Low temperature aqueous living/controlled (RAFT) polymerization of carboxybetaine methacrylamide up to high molecular weights.

Rodriguez-Emmenegger C, Schmidt BV, Sedlakova Z, Šubr V, Alles AB, Brynda E, Barner-Kowollik C.

Macromol Rapid Commun. 2011 Jul 1;32(13):958-65. doi: 10.1002/marc.201100176. Epub 2011 Jun 3.

PMID:
21648007
28.

Polymer brushes showing non-fouling in blood plasma challenge the currently accepted design of protein resistant surfaces.

Rodriguez-Emmenegger C, Brynda E, Riedel T, Houska M, Šubr V, Alles AB, Hasan E, Gautrot JE, Huck WT.

Macromol Rapid Commun. 2011 Jul 1;32(13):952-7. doi: 10.1002/marc.201100189. Epub 2011 Jun 3.

PMID:
21644241
29.

E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-α-activated human umbilical vein endothelial cells.

Bachtarzi H, Stevenson M, Subr V, Seymour LW, Fisher KD.

J Drug Target. 2011 Sep;19(8):690-700. doi: 10.3109/1061186X.2010.547585. Epub 2011 Feb 10.

PMID:
21309681
30.

Removable nanocoatings for siRNA polyplexes.

Kostka L, Konák C, Subr V, Spírková M, Addadi Y, Neeman M, Lammers T, Ulbrich K.

Bioconjug Chem. 2011 Feb 16;22(2):169-79. doi: 10.1021/bc100197e. Epub 2011 Jan 10.

PMID:
21218805
31.

HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations.

Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, Hennink WE, Storm G, Kiessling F.

Nanomedicine (Lond). 2010 Dec;5(10):1501-23. doi: 10.2217/nnm.10.130.

PMID:
21143030
32.

Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins.

Bachtarzi H, Stevenson M, Šubr V, Ulbrich K, Seymour LW, Fisher KD.

J Control Release. 2011 Mar 10;150(2):196-203. doi: 10.1016/j.jconrel.2010.10.011. Epub 2010 Oct 18.

33.

N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation.

Chytil P, Etrych T, Kříž J, Subr V, Ulbrich K.

Eur J Pharm Sci. 2010 Nov 20;41(3-4):473-82. doi: 10.1016/j.ejps.2010.08.003. Epub 2010 Aug 7.

PMID:
20696244
34.

Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation.

Hovorka O, Subr V, Větvička D, Kovář L, Strohalm J, Strohalm M, Benda A, Hof M, Ulbrich K, Ríhová B.

Eur J Pharm Biopharm. 2010 Nov;76(3):514-24. doi: 10.1016/j.ejpb.2010.07.008. Epub 2010 Jul 16.

PMID:
20638475
35.

Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells.

Kovar L, Etrych T, Kabesova M, Subr V, Vetvicka D, Hovorka O, Strohalm J, Sklenar J, Chytil P, Ulbrich K, Rihova B.

Tumour Biol. 2010 Aug;31(4):233-42. doi: 10.1007/s13277-010-0019-7. Epub 2010 Feb 24.

PMID:
20556593
36.

Chemical conjugation of cowpea mosaic viruses with reactive HPMA-based polymers.

Laga R, Konák C, Subr V, Ulbrich K, Suthiwangcharoen N, Niu Z, Wang Q.

J Biomater Sci Polym Ed. 2010;21(12):1669-85. doi: 10.1163/092050609X12547435571131. Epub 2010 Jun 9.

PMID:
20537248
37.

Structural and chemical aspects of HPMA copolymers as drug carriers.

Ulbrich K, Subr V.

Adv Drug Deliv Rev. 2010 Feb 17;62(2):150-66. doi: 10.1016/j.addr.2009.10.007. Epub 2009 Nov 18. Review.

PMID:
19931329
38.

Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers.

Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, Hennink WE, Storm G.

Biomaterials. 2009 Jul;30(20):3466-75. doi: 10.1016/j.biomaterials.2009.02.040. Epub 2009 Mar 21.

PMID:
19304320
39.

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy.

Lammers T, Subr V, Peschke P, Kühnlein R, Hennink WE, Ulbrich K, Kiessling F, Heilmann M, Debus J, Huber PE, Storm G.

Br J Cancer. 2008 Sep 16;99(6):900-10. doi: 10.1038/sj.bjc.6604561.

40.

Multifunctional cytotoxic stealth nanoparticles. A model approach with potential for cancer therapy.

Schneider GF, Subr V, Ulbrich K, Decher G.

Nano Lett. 2009 Feb;9(2):636-42. doi: 10.1021/nl802990w.

PMID:
19170551
41.

Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components.

Subr V, Kostka L, Selby-Milic T, Fisher K, Ulbrich K, Seymour LW, Carlisle RC.

J Control Release. 2009 Apr 17;135(2):152-8. doi: 10.1016/j.jconrel.2008.12.009. Epub 2008 Dec 30.

PMID:
19166885
42.

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.

Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK, Subr V, Ulbrich K, Gilbert RJ, Fisher KD, Finberg RW, Seymour LW.

Blood. 2009 Feb 26;113(9):1909-18. doi: 10.1182/blood-2008-09-178459. Epub 2009 Jan 8.

43.

Coating of vesicles with hydrophilic reactive polymers.

Konák C, Subr V, Kostka L, Stepánek P, Ulbrich K, Schlaad H.

Langmuir. 2008 Jul 15;24(14):7092-8. doi: 10.1021/la800119w. Epub 2008 Jun 11.

PMID:
18543996
44.

Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.

Ríhová B, Strohalm J, Hovorka O, Subr V, Etrych T, Chytil P, Pola R, Plocová D, Boucek J, Ulbrich K.

J Control Release. 2008 Apr 21;127(2):110-20. doi: 10.1016/j.jconrel.2008.01.003. Epub 2008 Jan 16.

PMID:
18325618
45.

Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera.

Carlisle RC, Benjamin R, Briggs SS, Sumner-Jones S, McIntosh J, Gill D, Hyde S, Nathwani A, Subr V, Ulbrich K, Seymour LW, Fisher KD.

J Gene Med. 2008 Apr;10(4):400-11. doi: 10.1002/jgm.1161.

PMID:
18220318
46.

Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.

Green NK, Morrison J, Hale S, Briggs SS, Stevenson M, Subr V, Ulbrich K, Chandler L, Mautner V, Seymour LW, Fisher KD.

J Gene Med. 2008 Mar;10(3):280-9. doi: 10.1002/jgm.1121.

PMID:
18214996
47.

Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.

Morrison J, Briggs SS, Green N, Fisher K, Subr V, Ulbrich K, Kehoe S, Seymour LW.

Mol Ther. 2008 Feb;16(2):244-51. Epub 2007 Dec 11.

48.

Reactive polymers for modification of biologically active molecules and gene delivery vectors.

Ulbrich K, Laga R, Subr V.

J Control Release. 2006 Nov 28;116(2):e3-5. No abstract available.

PMID:
17718954
49.

Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy.

Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, Seymour LW.

J Drug Target. 2007 Aug-Sep;15(7-8):546-51.

PMID:
17671901
50.

Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems.

Lammers T, Peschke P, Kühnlein R, Subr V, Ulbrich K, Debus J, Huber P, Hennink W, Storm G.

J Control Release. 2007 Feb 26;117(3):333-41. Epub 2006 Nov 25.

PMID:
17215057

Supplemental Content

Support Center